Goldman Sachs: Curing Patients' Illnesses Is Bad for Business
As CNBC originally reported, Goldman Sachs
published a report on April 10 called “The Genome Revolution,” which evaluated the question, “Is curing patients a sustainable business model?” Analyst Salveen Richter explained that new forms of
long-term cures involving gene therapy may be good for humanity, but bad for capitalism.
“The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies,” Richter wrote. “While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.”